Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral LDE225 in hedgehog-pathway activated relapsed medulloblastoma
NL-OMON39614Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2014
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonidegib in medulloblastoma, sponsored by Novartis. Primary endpoint: Overall response rate by independent central review. Started Jul 2014; status: active, not recruiting.
02
Drugs
sonidegib
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NL-OMON39614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39614.